Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 05/31/2024 | 96,493,078 | Total gross of voting rights: 96,493,078 |
| Total net* of voting rights: 96,236,383 |
* Net total = total number of voting rights attached to shares – shares without voting rights
| Last Trade: | US$5.21 |
| Daily Change: | 0.33 6.76 |
| Daily Volume: | 47,687 |
| Market Cap: | US$106.910M |
January 08, 2025 December 11, 2024 November 06, 2024 October 22, 2024 September 23, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
